Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial
Listen to this summary
The authors aimed to evaluate the efficacy and safety of prophylactic tirofiban, a glycoprotein IIb/IIIa inhibitor, in reducing thromboembolic complications during neurointerventional therapy for unruptured intracranial aneurysms. In a phase 2 trial involving 191 patients, the study found that adjunctive tirofiban significantly decreased the median volume of new ischemic lesions without increasing the risk of hemorrhagic complications or mortality. These promising results suggest the need for further validation in larger, multicenter trials.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Stroke
View all →Jun 12, 2026 · Stroke
Neurotransmitter-Informed Connectome Approach to Language Impairment After Stroke
Jun 10, 2026 · Stroke
Accuracy of Machine Learning to Predict Upper-Limb Outcome Within the First 72 Hours Poststroke
May 29, 2026 · Stroke
Intensive Versus Conventional Blood Pressure Lowering After Successful Endovascular Thrombectomy: OPTIMAL-BP 1-Year Outcomes
More in Psychiatry & Neurology
View all →Nov 20, 2026 · Journal of pain and symptom management
ACCOMPANI: A Psychosocial Nurse Intervention for African American Families in Pediatric Oncology.
Nov 20, 2026 · Journal of pain and symptom management
Perceived Clinical Utility of a Routine Family Experience Feedback Loop in Pediatric Palliative Care.
Nov 20, 2026 · Journal of pain and symptom management
Predictors of Clinician Success, Quality, and Resilience in Outpatient Pediatric Palliative Care.
Nov 19, 2026 · Developmental medicine and child neurology
Definition and classification of cerebral palsy operationalized by the Surveillance of Cerebral Palsy in Europe.
Nov 19, 2026 · Journal of pain and symptom management
Dementia and Unwanted End-of-Life Treatment: A Retrospective Cohort Study Among Older Adults.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


